When integrating mutation data from ten oncogenic signaling pathways, it was observed that the mutation rates of classic tumor suppressor genes such as TP53, STK11, and AXIN1/2 were significantly elevated in the high-MLEM group. This evidence concerns the gene TP53 and neoplasm.